简介：在病人作为首要或第二线的治疗评估paclitaxel，cisplatin和5-FU(PCF)的联合政体的功效和毒性与的目的进展胃并且在中国的esophagogastric连接(EGJ)腺癌。病人与paclitaxel被对待的方法d1上的150mg/m2；fractionatedcisplatin15mg/m2和连续注入5-FU600mg/(m2朠楬污映扩楲汬牡????????????М

简介：

简介：Bevacizumabisoneoftheraredrugsthatcouldimprovehigh-gradegliomaoutcomeafterfailureofchemoradiotherapy.However,todate,thereisnobiomarkerpredictiveforefficacyofbevacizumabtherapyintermsofsurvivalimprovementforpatientswithhigh-

简介：Astodeterminetheeffectofpost-remissiontherapyinprolongingsurvivalanddurationofremissionaftercompleteremission,50patientswithAPLIncompleteremissionInducedbyretinolcacid(RA)weredividedintothreegroupsrandomly:(A)30cases,treatedbyalternatechemotherapywithRA;(B)10cases,withRAalone;(C)10cases,onlywithchemotherapy.ThesurvivalcurvesshowedmatGroupAhadthesurvivaltimemorethan1yearIn87.4%,morethan2yearin80.7%.26/30casesweresurvivalandstillinremission,thesurvivalcurvetendtobeaplateauat16months.InGroupBmorethan1yearin45.7%.InGroupC,morethan1yearIn50%.(Keplan-Melerx2=8.93P<0.01).ThisresultshowedthatthealternatechemotherapywithRAforpost-InductionremissiontherapycouldbeusefultoImprovelong-termsurvivorsandtoprolongthedurationofremission.

简介：Objective:Todeterminetheclinicalserumlevelsofcarcinoembryonicantigen(CEA)andcarbohydrateantigen19-9(CA19-9),individuallyandincombination,forthediagnosisof50healthysubjectsand150casesofesophageal,gastric,andcoloncancers.Methods:Thesensitivitiesofthetwomarkerswerecomparedindividuallyandincombination,withspecificitysetat100%.Receiveroperatingcharacteristic(ROC)curveswereplotted.Results:SerumCEAlevelsweresignificantlyhigherincancerpatientsthaninthecontrolgroup.ThesensitivityofCEAwasdetermined:inesophagealcancer,sensitivity=28%,negativepredictivevalue(NPV)=61.72%,andAUC=0.742(SE=0.05),withasignificancelevelofP<0.0001;ingastriccancer,sensitivity=30%,NPV=58.82%,andAUC=0.734(SE=0.05),withasignificancelevelofP<0.0001;incoloncancer,sensitivity=74%,NPV=79.36%,andAUC=0.856(SE=0.04),withasignificancelevelofP<0.0001.ThesensitivityofCA19-9wasalsoevaluated:inesophagealcancer,sensitivity=18%,NPV=54.94%,andAUC=0.573(SE=0.05),withasignificancelevelofP=0.2054.Ingastriccancer,sensitivity=42%,NPV=63.29%,andAUC=0.679(SE=0.05),withasignificancelevelofP<0.0011.Incoloncancer,sensitivity=26%,NPV=57.47%,andAUC=0.580(SE=0.05),withasignificancelevelofP=0.1670.ThefollowingwerethesensitivitiesofCEA/CA19-9combined:inesophagealcancer,sensitivity=42%,NPV=63.29%,SE=0.078(95%CI:0.0159-0.322);gastriccancer,sensitivity=58%,NPV=70.42%,SE=0.072(95%CI:-0.0866-0.198);andcoloncancer,sensitivity=72%,NPV=78.12%,SE=0.070(95%CI:0.137-0.415).Conclusion:CEAexhibitedthehighestsensitivityforcoloncancer,andCA19-9exhibitedthehighestsensitivityforgastriccancer.Combinedanalysisindicatedanincreaseindiagnosticsensitivityinesophagealandgastriccancercomparedwiththatincoloncancer.

简介：Objective:Anti-angiogenicdrugsareanemergingtreatmentoptionagainstmalignanttumors.Theaimofthisstudywastodeterminewhethertheadditionofperioperativerh-endostatintochemotherapycouldimprovetheprobabilityofdistantmetastasis-freesurvival(DMFS)andoverallsurvival(OS)inpatientsnewlydiagnosedwithnon-metastaticconventionalosteosarcoma.Methods:Thiswasacontrollednon-randomizedclinicalstudythatincluded388patientswithoutclinicallydetectablemetastaticdiseaseenrolledfromJanuary2008toApril2012.Thecontroltreatmentgrouphad272patients;180weremaleand92,female,withamedianageof17years.Thetreatmentgrouphad58patients;36weremaleand22,female,withamedianageof16years.Thecontrolgroupreceivedpreoperativechemotherapyfollowedbysurgeryandpostoperativechemotherapy.Thetreatmentgroupreceived4cyclesofrh-endostatinperioperativelyinadditiontochemotherapyasperthecontrolgroup.Patientswerefollowedupfrom6-101monthswithamedianfollow-upperiodof50.2months.Results:The5-yearDMFSofthecontrolgroup(61%)wassignificantlylowerthanthatoftherh-endostatingroup(79%)(P=0.013).The5-yearOSofthecontrolgroup(74%)wassignificantlylowerthanthatoftherh-endostatintreatmentgroup(87%)(P=0.029).Nodifferenceinadversedrugreactionswasfoundbetweenthese2groups.Conclusions:Theadditionofperioperativerh-endostatintochemotherapycouldsignificantlyimprovetheDMFSandOSofpatientswithnon-metastaticosteosarcoma.

简介：Objective:Thisrandomizedstudyaimedtocomparetheclinicalefficacybetweenthenoveldualtracercomposedofindocyaninegreen(ICG)andbluedye(BD)andtheconventionaldualtracercomposedofradioisotopeandBDforsentinellymphnode(SLN)mappinginpatientswithbreastcancer.Methods:Thisstudyenrolled471clinicallylymphnode-negativepatientswithprimarybreastcancer.Allpatientsunderwentmastectomy,andthoseundergoingsentinellymphnodebiopsy(SLNB)wererandomizedtoreceivebluedyeplusradioisotope(RBgroup)orBDplusICG(IBgroup).ThedetectionperformancesonSLNidentificationrate,positiveSLNcounts,detectionsensitivity,andfalse-negativeratewerecomparedbetweenthetwogroups.Results:IntheIBgroup,97%(194/200)ofthepatientswhounderwenttheICGandBDdualtracerinjectionshowedfluorescentpositivelymphaticvesselswithin2–5min.TheidentificationrateofSLNswascomparablebetweentheIBgroup(99.0%,198/200)andtheRBgroup(99.6%,270/271)(P=0.79).NosignificantdifferenceswereobservedintheidentificationrateofmetastaticSLNs(22.5%vs.22.9%,P>0.05,RBgroupvs.IBgroup,thesamebelow),positiveSLNcounts(3.72±2.28vs.3.91±2.13,P>0.05),positivemetastaticSLNcounts(0.38±0.84vs.0.34±0.78,P>0.05),SLNBdetectionsensitivity(94.4%vs.92.5%,P>0.05),orfalse-negativerate(5.6%vs.7.5%,P>0.05)betweenthetwogroups.Conclusions:ICGcanbeusedasapromisingalternativetracerforradioisotopeinSLNmapping,andwhenitiscombinedwithBDinlymphangiography,itofferscomparabledetectionsensitivitycomparedtotheconventionallymphaticmappingstrategiesthatarewidelyusedinclinicalpractice.

简介：Objective:Therecurrenceorprogressionunderendocrinetherapyinhormonereceptor-positive(HR+)advancedbreastcancer(ABC)remainedacriticalclinicalchallenge.Chidamideisanoralsubtype-selectivehistonedeacetylase(HDAC)inhibitorwithmultiplefunctionsintumorgrowthinhibitionandmicroenvironmentmodulationviaepigeneticreprogramming.Thepurposeofthisstudywastoevaluatethesafety,pharmacokinetics(PK),andpreliminaryefficacyofchidamideincombinationwithexemestaneinHR+ABCpatients.Methods:EligiblepatientswerepostmenopausalwomenwithHR+ABCrecurrentorprogressedtoatleastoneendocrinetherapy.Bloodsampleswereobtainedintherun-inperiodandthefirstdayofcombinationtreatmentforPKanalysis.Incombinationtreatment,patientsweregivenexemestane25mgdailyandchidamide30mgtwiceaweek(BIW)untilprogressionofdiseaseorintolerabletoxicities.Atreatmentcyclewasdefinedas4weeks.Safety,PKparameters,andpreliminaryefficacywereevaluated.Results:Atotalof20patientswereenrolledbetweenJulyandDecember,2015.Themediannumberoftreatmentscyclewas5.2(20.8weeks)with2patientsstillontreatmentatthedatacut-offdateofOctober,2017.Thetreatment-relatedadverseevents(AE)≥grade3inmorethan2patientswereneutropenia(35%),thrombocytopenia(30%),andleucopenia(20%).Theplasmaexposureofexemestanewasconsistentinthepresenceorabsenceofchidamide.Aslightincreaseinchidamideexposurewasnotedinthepresenceofexemestane,probablyduetotheinter-andintra-patientvariations.Thebestresponsein16evaluablepatientswasassessedbyResponseEvaluationCriteriainSolidTumors(RECIST),including4patientswithpartialresponse,10patientswithstabledisease.Themedianprogression-freesurvival(PFS)was7.6months.Conclusions:ThecombinationofchidamidewithexemestanewasgenerallywelltoleratedwithpromisingpreliminaryefficacyinHR+ABCpatients.Theoverallresultsfromthisstudyencouragefurtherpivotaltrialinthispatie

简介：Objective:ToevaluatethefeasibilityofDNAimagecytometry(DNA-ICM)asaprimaryscreeningmethodforesophagealsquamouscellcancer(ESCC).Methods:Atotalof5,382localresidentsaged40–69yearsfromthreehigh-riskareasinChina(LinzhouinHenanprovince,FeichenginShandongprovinceandCixianinHebeiprovince)from2008to2011wererecruitedinthispopulation-basedscreeningstudy.And2,526subjectsdeclinedtoreceiveendoscopicbiopsyexaminationwithLugol'siodinestaining,while9and815subjectswereexcludedfromliquid-basedcytologyandDNA-ICMtestrespectivelyduetoslidequality.Finally,2,856,5,373and4,567subjectswereenrolledintheanalysisforendoscopicbiopsyexamination,liquid-basedcytologyandDNA-ICMtest,respectively.Sensitivity(SE),specificity(SP),negativepredictivevalues(NPV)andpositivepredictivevalues(PPV)aswellastheir95%confidenceintervals(95%CI)forDNA-ICM,liquid-basedcytologyandthecombinationofthetwomethodswerecalculated.Receiveroperatingcharacteristic(ROC)curveswereappliedtodeterminethecutoffpointofDNA-ICMforesophagealcancer.Results:DNA-ICMresultsweresignificantlycorrelativewithesophagealcancerandprecancerlesions(χ~2=18.016,P<0.001).Thecutoffpointswere5,802,5,803and8,002basedondissimilarpathologicaltypesoflowgradeintraepithelialneoplasia(LGIN),highgradeintraepithelialneoplasia(HGIN),andESCC,respectively,and5,803waschoseninthisstudyconsideringtheSEandSP.TheSE,SP,PPV,NPVofDNA-ICMtest(cutoffpoint5,803)combinedwithliquid-basedcytology[thresholdatypicalsquamouscellsofundeterminedsignificance(ASCUS)]wereseparately72.1%(95%CI:70.3%-73.9%),43.3%(95%CI:41.3%-45.3%),22.8%(95%CI:21.1%-24.5%)and87.0%(95%CI:85.7%-88.3%)forLGIN,85.7%(95%CI:84.3%-87.1%),41.3%(95%CI:39.3%-43.3%),4.6%(95%CI:3.8%-5.4%)and98.9%(95%CI:98.5%-99.3%)forHGIN,and96.0%(95%CI:95.2%-96.8%),40.8%(95%CI:38.8%-42.8%),1.7%(95%CI:1.2%-2.2%)and99.9%

简介：

简介：这研究试图表示白喉毒素和人的熔化蛋白质的目的在Escherichiacoli的B激活房间的因素(DT388sBAFF)(E。coli)并且在人的B系尖锐成淋巴细胞的白血病调查它的活动1个房间(BALL-1)。

简介：

简介：